Lupin Ltd

LUPIN

Company Profile

  • Business description

    Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.

  • Contact

    Off. Western Express Highway
    3rd floor, Kalpataru Inspire
    Santacruz (East)
    MumbaiMH400055
    IND

    T: +91 2266402323

    E: [email protected]

    https://www.lupin.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 March 2026

    Employees

    24,006

Stocks News & Analysis

stocks

Are we as bullish on Oracle as the market?

Shares jumped in response to the latest results.
stocks

Anglo American strikes deal to create a new copper giant

We are surprised that Teck agreed to the merger on these terms, and wouldn’t be surprised if there is a twist in the tale.
stocks

The ‘other’ AI chip behemoth that might just be getting started

The magnitude of growth at Broadcom continues to astound us.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,071.409.10-0.10%
CAC 407,838.1776.850.99%
DAX 4023,721.2888.330.37%
Dow JONES (US)45,490.92220.42-0.48%
FTSE 1009,269.6544.260.48%
HKSE26,086.32113.94-0.43%
NASDAQ21,886.066.570.03%
Nikkei 22544,372.50534.831.22%
NZX 50 Index13,229.1547.09-0.35%
S&P 5006,532.040.000.00%
S&P/ASX 2008,805.008.80-0.10%
SSE Composite Index3,875.3163.091.65%

Market Movers